---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-126067"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2022-12-12T23:59:59+00:00"
generated_at: "2026-06-21T06:07:24.934701+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Theravance Biopharma CFO Andrew Hindman to depart Dec 31; Aziz Sawaf named successor

## Summary
- Andrew Hindman, SVP and CFO, will leave on December 31, 2022.
- Aziz Sawaf appointed CFO effective Jan 1, 2023; previously VP of Finance since Oct 2021.
- Sawaf joined Theravance in 2014; prior roles at Gilead Sciences, Amgen, and consulting.
- Sawaf holds CFA charter, MBA from USC, and MBEE from Johns Hopkins University.

## SEC filing metadata
- accession: 0001104659-22-126067
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2022-12-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465922126067/0001104659-22-126067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465922126067/tm2232423d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-126067
- JSON: https://secwatch.observer/filing/0001104659-22-126067.json
- Plain text: https://secwatch.observer/filing/0001104659-22-126067.txt

## Key facts
- Executive change
  Andrew A. Hindman changed role as Senior Vice President and Chief Financial Officer at Theravance Biopharma, Inc..
  - Action: will transition
  - Role: Senior Vice President and Chief Financial Officer
  source text: Andrew A. Hindman, Senior Vice President and Chief Financial Officer, will transition from the Company on December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465922126067/0001104659-22-126067-index.htm
- Executive change
  Aziz Sawaf was appointed as Chief Financial Officer at Theravance Biopharma, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: The Company has appointed Aziz Sawaf, CFA as the Company’s Chief Financial Officer, effective immediately following Mr. Hindman’s departure.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465922126067/0001104659-22-126067-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.